Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753831 | 0.89 | SCD (0.47) | SCDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10098391 | 0.88 | MEN1 (0.46) | SMN1; SMN2TP53CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2368467 | 0.82 | PTGDR2 (0.48) | SMN1; SMN2TP53GAAMAPTPOLB | |
| SCHEMBL3751671 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2TP53GAALMNAMAPT | |
| SCHEMBL3653768 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53GAALMNAMAPT | |
| SCHEMBL3650305 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53GAALMNAMAPT | |
| SCHEMBL3746392 | 0.79 | KMT2A (0.46) | SMN1; SMN2TP53GAALMNAMAPT | |
| SCHEMBL2367728 | 0.79 | KDM4E (0.50) | SMN1; SMN2TP53KCNH2MAPTPOLB | |
| SCHEMBL31414372 | 0.79 | KDM4E (0.50) | SMN1; SMN2TP53KCNH2MAPTPOLB | |
| SCHEMBL3658937 | 0.78 | SCD (0.39) | SCDSMN1; SMN2TP53GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | claimed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | claimed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | claimed |
| EP-2207774-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GlaxoSmithKline LLC (US) | 2010-07-21 | — | — | EP | claimed |
| WO-2009060054-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| EP-2207774-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GlaxoSmithKline LLC (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009060054-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297097-A1 | COMPOUNDS | APP, BACE1, SCD | SCD 3/4885SMN1; SMN2 3780/4885TP53 1018/4885 |
| US-20120225878-A1 | COMPOUNDS | CYP11B2, CYP11B1, SCD | SCD 3/4885SMN1; SMN2 1592/4885TP53 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.